Novel Insights into Diagnosis and Therapy of Advanced Renal Cell Carcinoma
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 16
Special Issue Editor
Interests: kidney cancer; prostate cancer; kidney transplantation; metabolomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Renal cell carcinoma (RCC) is the most common type of kidney cancer, and in recent years, there has been a growing interest in identifying tumor markers not only for diagnostic purposes but also to improve the predictive power of clinical and pathological parameters. The progressive introduction of high-throughput technologies has led to a greater understanding of molecular mechanisms underlying the development of RCC and the identification of novel potential therapeutic targets.
The treatment landscape for advanced or metastatic RCC is rapidly evolving, with risk stratification being a crucial step in developing a treatment plan. Cytoreductive nephrectomy (CN) and surgical metastasectomy are still considered fundamental treatments in selected cases after evaluation by a multidisciplinary team. However, recent studies have shown that CN may not always be necessary, especially with the availability of systemic therapies like immune checkpoint inhibitor-based combinations that have shown superior outcomes compared to monotherapy with tyrosine kinase inhibitors.
This Special Issue of Biomedicines is dedicated to studies exploring the application of different approaches to understand the alterations in biological systems occurring in the pathogenesis of advanced RCC, as well as minimally invasive treatment and translational research for the diagnosis and management of this tumor.
Prof. Dr. Giuseppe Lucarelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- renal cell carcinoma
- kidney cancer
- therapeutic targets
